Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS). MS is characterised by damage to myelin, but there are no approved therapies… Read More
In this advertorial, Dr John Stenson from Malvern Panalytical explains why we need to move away from using ‘SLS mode’ on DLS instruments to determine B22 stability values for biologics. Reliable stability data: A growing need Stability testing for biologics is undergoing something of a revolution, with the… Read More
Shionogi has announced plans to acquire IntraBio, a biopharmaceutical company developing therapies for neurodegenerative diseases, for $2 billion. The transaction will add Aqneursa (levacetylleucine) and IntraBio’s capabilities in the rare disease area to Shionogi’s growing portfolio. Aqneursa was approved by the FDA in September 2024… Read More
The Association of the British Pharmaceutical Industry (ABPI) has launched its first Youth Advisory Council, a new advisory body made up of young people aged 16 to 19 from across the UK, tasked with challenging and shaping how the pharmaceutical industry inspires, engages and communicates with the next generation. Read More
Eli Lilly and Gate Bioscience have expanded their collaboration to discover, develop, and commercialise molecular gate therapeutics. The expanded collaboration adds one target, with the opportunity to add a second target, to the companies’ existing work. The programmes leverage Gate’s Molecular Gate drug discovery engine… Read More
MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma. The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More
Ahead of the Budget, UK life sciences groups have called on the Chancellor to prioritise investment in new medicines. The UK government has set out bold targets for the UK’s life sciences sector. By 2030, it wants the UK to lead Europe in commercial research and development… Read More
Biopharma dealmaking confidence is strengthening, a new survey has revealed, but access to capital remains the defining challenge. BIO-Europe’s Biopharma C-Suite Agenda Survey 2026 surveyed 81 senior biopharma executives, including 50 CEOs. The survey results demonstrate that 75% expect partnering and M&A appetite to increase… Read More
Peptide therapeutics, while one of the fastest growing drug modalities, are challenging to formulate, due to heir conformational flexibility, propensity for aggregation and fibrillation, and sensitivity to pH. In this Application Note from Nanotemper, learn how to: Simultaneously assess thermal and colloidal stability to reveal early self-association propensity Compare finished-product… Read More
Cancer Research UK has signed an agreement with ORIC Pharmaceuticals to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase I/II clinical trial of ORIC-259, including… Read More
Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy. The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours. … Read More
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion channels and optogenetics”. It was jointly presented to Karl Deisseroth, The Howard Hughes Medical Institute and Stanford University, USA; Peter Hegemann, Humboldt… Read More
The global informatics market is expected to triple in size in the next ten years. These technologies are speeding up the process of drug development, but also enabling better accuracy, more precision, more reproducibility and ultimately, better science. This eBook explores the latest developments in artificial… Read More
Atrogi has revealed positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator. ATR-258 is designed to target skeletal muscle through a novel GRK2-biased signalling mechanism, with the goal of improving body composition by reducing fat mass while… Read More
Despite their challenging nature, cell & gene therapies (CGTs) are becoming ever more successful and accessible one-time treatments for haematological malignancies and genetic diseases, while researchers have recently made significant strides forward in their use to treat other cancers.
SciBrunch Therapeutics and MSD (or Merck & Co) have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the agreement, SciBrunch has granted MSD exclusive rights to develop, manufacture and commercialise SPR2015 worldwide. SciBrunch will receive… Read More
